BERINERT® (C1-Esterase Inhibitor) is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of HAE attacks in adult and pediatric patients. Berinert is delivered intravenously and is approved for self-administration. The manufacturer, CSL Behring, provides further details on their product list page.

Adults and children
Self-administered

Intravenous
FIRAZYR® (icatibant injection) is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of HAE in adults, adolescents and children aged 2 years and older with C1-esterase inhibitor deficiency. Firazyr is delivered by subcutaneous injection and is approved for self-administration. The manufacturer, Takeda, provides further details on their product page.

Adults and children
Self-administered
Subcutaneous
CINRYZE® (C1 inhibitor) is indicated for routine prevention against HAE attacks in adults, adolescents and pediatric patients (6 years of age and older). Cinryze is delivered intravenously and is approved for self-administration. The manufacturer, Takeda, provides further details on their product page.

Adults and children
Self-administered

Intravenous
HAEGARDA® (C1-Esterase Inhibitor Subcutaneous) is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) indicated for routine prevention of HAE attacks in adults and adolescents. Heagarda is delivered by subcutaneous injection and is approved for self-administration. The manufacturer, CSL Behring, provides further details on their product list page.

Adults and adolescents
Self-administered
Subcutaneous
ORLADEYO™ (Berotralstat capsule) is a plasma kallikrein inhibitor indicated for routine prevention of HAE attacks in adults and pediatric patients 12 years and older. ORLADEYO is taken orally once daily. The manufacturer, BioCryst, provides further details here.

Adults and adolescents
Self-administered
Oral
TAKHZYRO™ (lanadelumab injection) is a plasma kallikrein inhibitor (monoclonal antibody) indicated for routine prevention of HAE attacks in patients 12 years and older. TAKHZYRO is administered by subcutaneous injection and is approved for self-administration. The manufacturer, Takeda, provides further details on their product page.

Adults and adolescents
Self-administered
Subcutaneous
Tranexamic acid is an anti-fibrinolytic agent taken orally. Further details can be found in the International / Canadian HAE Guidelines.
Self-administered
Oral

Please make an appointment with your HAE specialist if you need a prescription for an HAE treatment. Family physicians cannot prescribe HAE treatments.
If you think you may have HAE and do not yet have a specialist, the first step is to visit your family physician. They can refer you to an HAE specialist. If you and/or your family physician need help finding an HAE specialist in your area, please refer to the Canadian HAE Network (CHAEN)‘s website where you will find a list of HAE treating physicians who are members of CHAEN.
IMPORTANT: Patients with the slightest hint of throat swelling should seek immediate treatment to ensure that their airway is not compromised. Medicines used to treat swelling from allergies, such as corticosteroids (prednisone), antihistamines, and epinephrine are not effective treatments for HAE.